DD207196A5 - Verfahren zur herstellung von neuen cis- bicyclo (3.3.0) octanderivaten - Google Patents

Verfahren zur herstellung von neuen cis- bicyclo (3.3.0) octanderivaten Download PDF

Info

Publication number: DD207196A5
Authority: DD; German Democratic Republic
Prior art keywords: radical; formula; compounds; compound; bicyclo
Prior art date: 1981-11-21

Application number

DD82245014A

Other languages

German (de)

English (en)

Inventor

Boehlke

Loschen

Michel

Mueller

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-11-21

Filing date

1982-11-18

Publication date

1984-02-22

1982-11-18 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

1984-02-22 Publication of DD207196A5 publication Critical patent/DD207196A5/de

Links

238000002360 preparation method Methods 0.000 title claims description 15
238000000034 method Methods 0.000 title claims description 11
230000008569 process Effects 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims abstract description 49
239000001257 hydrogen Substances 0.000 claims abstract description 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
125000006239 protecting group Chemical group 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
150000001768 cations Chemical class 0.000 claims abstract description 4
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims abstract description 3
229910052799 carbon Inorganic materials 0.000 claims abstract description 3
-1 alkyl radical Chemical class 0.000 claims description 33
238000006243 chemical reaction Methods 0.000 claims description 10
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 9
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 claims description 5
230000007717 exclusion Effects 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
150000003254 radicals Chemical class 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 3
UXBIXOXDACBTDG-UHFFFAOYSA-N 1-adamantyl radical Chemical compound C1C(C2)CC3C[C]1CC2C3 UXBIXOXDACBTDG-UHFFFAOYSA-N 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
239000000010 aprotic solvent Substances 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract description 12
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 10
230000036772 blood pressure Effects 0.000 abstract description 5
239000003814 drug Substances 0.000 abstract description 5
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract description 3
AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical class C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 abstract description 2
239000003112 inhibitor Substances 0.000 abstract description 2
125000000217 alkyl group Chemical group 0.000 abstract 1
210000001772 blood platelet Anatomy 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
239000000126 substance Substances 0.000 description 28
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 17
229960001123 epoprostenol Drugs 0.000 description 17
239000000047 product Substances 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 16
239000000203 mixture Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
238000004440 column chromatography Methods 0.000 description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000002776 aggregation Effects 0.000 description 9
238000004220 aggregation Methods 0.000 description 9
238000003756 stirring Methods 0.000 description 9
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
230000009471 action Effects 0.000 description 8
230000001077 hypotensive effect Effects 0.000 description 8
239000003480 eluent Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229910052938 sodium sulfate Inorganic materials 0.000 description 6
235000011152 sodium sulphate Nutrition 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229960000583 acetic acid Drugs 0.000 description 5
239000012230 colorless oil Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000007789 gas Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
239000011734 sodium Substances 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
IVOMOUWHDPKRLL-KQYNXXCUSA-M 3',5'-cyclic AMP(1-) Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-M 0.000 description 4
RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
229910004283 SiO 4 Inorganic materials 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000000926 separation method Methods 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
RJADQDXZYFCVHV-JQMWNLLFSA-N 5-[(2s,4r,5r,6ar)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]furan-2-yl]pentanoic acid Chemical compound O1[C@@H](CCCCC(O)=O)CC2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@H]21 RJADQDXZYFCVHV-JQMWNLLFSA-N 0.000 description 3
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical compound C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
230000003276 anti-hypertensive effect Effects 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
208000021822 hypotensive Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
OLTPSBJPRFGSGJ-UHFFFAOYSA-M (3-methoxycarbonylphenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].COC(=O)C1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 OLTPSBJPRFGSGJ-UHFFFAOYSA-M 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
206010003178 Arterial thrombosis Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
229910004664 Cerium(III) chloride Inorganic materials 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
230000006502 antiplatelets effects Effects 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000009835 boiling Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
230000009467 reduction Effects 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
IFKPLJWIEQBPGG-QGZVFWFLSA-N (5s)-6-(dimethylamino)-5-methyl-4,4-diphenylhexan-3-one Chemical compound C=1C=CC=CC=1C([C@H](C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-QGZVFWFLSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022714 Intestinal ulcer Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
QKNDAUTYSODFJV-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;sodium Chemical compound [Na].C[Si](C)(C)N[Si](C)(C)C QKNDAUTYSODFJV-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000009843 endothelial lesion Effects 0.000 description 1
SYEXGNJRYPOUSI-UHFFFAOYSA-N ethyl adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1(C(=O)OCC)C3 SYEXGNJRYPOUSI-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000006256 n-propyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
150000004714 phosphonium salts Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000011699 spontaneously hypertensive rat Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000037905 systemic hypertension Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
- C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
- C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

DD82245014A 1981-11-21 1982-11-18 Verfahren zur herstellung von neuen cis- bicyclo (3.3.0) octanderivaten DD207196A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3146278A DE3146278C2 (de)	1981-11-21	1981-11-21	cis-Bicyclo[3.3.0]octanderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen

Publications (1)

Publication Number	Publication Date
DD207196A5 true DD207196A5 (de)	1984-02-22

Family

ID=6146953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD82245014A DD207196A5 (de)	1981-11-21	1982-11-18	Verfahren zur herstellung von neuen cis- bicyclo (3.3.0) octanderivaten

Country Status (21)

Country	Link
US (1)	US4510323A (pl)
EP (1)	EP0080061B1 (pl)
JP (1)	JPS5892637A (pl)
AT (1)	ATE11668T1 (pl)
AU (1)	AU556560B2 (pl)
CA (1)	CA1202968A (pl)
DD (1)	DD207196A5 (pl)
DE (2)	DE3146278C2 (pl)
DK (1)	DK155934C (pl)
ES (1)	ES8308299A1 (pl)
GR (1)	GR77643B (pl)
HK (1)	HK40488A (pl)
HU (1)	HU187814B (pl)
IE (1)	IE53785B1 (pl)
MY (1)	MY8700890A (pl)
PL (1)	PL137185B1 (pl)
PT (1)	PT75694B (pl)
SG (1)	SG5788G (pl)
SU (1)	SU1225482A3 (pl)
YU (1)	YU42604B (pl)
ZA (1)	ZA826928B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3408699A1 (de) *	1984-03-08	1985-09-12	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3914735A1 (de) *	1989-05-05	1990-11-08	Gruenenthal Gmbh	Pharmakologisch wirksame ester, diese enthaltende arzneimittel und die herstellung dieser ester und arzneimittel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201699A (en) *	1922-06-02	1923-08-09	Joseph Gardner	Improvements in mechanical lubricators
DE2912409A1 (de) *	1978-03-31	1979-10-11	Ono Pharmaceutical Co	6,9-methano-pgi tief 2 -analoge
CA1201712A (en) *	1980-02-28	1986-03-11	Paul A. Aristoff	Carbacyclin analogs
JPS56145239A (en) *	1980-04-11	1981-11-11	Sumitomo Chem Co Ltd	Novel bicyclooctane derivative and its preparation

1981
- 1981-11-21 DE DE3146278A patent/DE3146278C2/de not_active Expired
1982
- 1982-09-15 IE IE2252/82A patent/IE53785B1/en not_active IP Right Cessation
- 1982-09-20 GR GR69316A patent/GR77643B/el unknown
- 1982-09-21 ZA ZA826928A patent/ZA826928B/xx unknown
- 1982-09-21 CA CA000411873A patent/CA1202968A/en not_active Expired
- 1982-09-28 AU AU88813/82A patent/AU556560B2/en not_active Ceased
- 1982-10-18 DE DE8282109592T patent/DE3262233D1/de not_active Expired
- 1982-10-18 EP EP82109592A patent/EP0080061B1/de not_active Expired
- 1982-10-18 PT PT75694A patent/PT75694B/pt not_active IP Right Cessation
- 1982-10-18 AT AT82109592T patent/ATE11668T1/de not_active IP Right Cessation
- 1982-10-28 SU SU823505874A patent/SU1225482A3/ru active
- 1982-11-17 HU HU823681A patent/HU187814B/hu not_active IP Right Cessation
- 1982-11-17 US US06/442,240 patent/US4510323A/en not_active Expired - Fee Related
- 1982-11-18 PL PL1982239099A patent/PL137185B1/pl unknown
- 1982-11-18 DK DK513982A patent/DK155934C/da not_active IP Right Cessation
- 1982-11-18 DD DD82245014A patent/DD207196A5/de not_active IP Right Cessation
- 1982-11-18 YU YU2578/82A patent/YU42604B/xx unknown
- 1982-11-20 JP JP57202906A patent/JPS5892637A/ja active Granted
- 1982-11-20 ES ES517545A patent/ES8308299A1/es not_active Expired
1987
- 1987-12-30 MY MY890/87A patent/MY8700890A/xx unknown
1988
- 1988-01-25 SG SG57/88A patent/SG5788G/en unknown
- 1988-06-02 HK HK404/88A patent/HK40488A/xx unknown

Also Published As

Publication number	Publication date
US4510323A (en)	1985-04-09
AU556560B2 (en)	1986-11-06
ATE11668T1 (de)	1985-02-15
HK40488A (en)	1988-06-10
DE3146278C2 (de)	1984-10-31
PT75694B (de)	1985-01-10
JPH0336821B2 (pl)	1991-06-03
YU42604B (en)	1988-10-31
SG5788G (en)	1989-06-02
DK513982A (da)	1983-05-22
DK155934B (da)	1989-06-05
ES517545A0 (es)	1983-08-16
HU187814B (en)	1986-02-28
ES8308299A1 (es)	1983-08-16
ZA826928B (en)	1983-11-30
DK155934C (da)	1989-10-09
GR77643B (pl)	1984-09-25
EP0080061B1 (de)	1985-02-06
IE53785B1 (en)	1989-02-15
AU8881382A (en)	1983-05-26
MY8700890A (en)	1987-12-31
PT75694A (de)	1982-11-01
DE3262233D1 (en)	1985-03-21
IE822252L (en)	1983-04-21
PL137185B1 (en)	1986-05-31
JPS5892637A (ja)	1983-06-02
CA1202968A (en)	1986-04-08
PL239099A1 (en)	1983-05-23
DE3146278A1 (de)	1983-06-01
YU257882A (en)	1985-03-20
SU1225482A3 (ru)	1986-04-15
EP0080061A1 (de)	1983-06-01

Legal Events

Date	Code	Title	Description
1995-10-12	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0055208B1 (de)	1985-03-13	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CH647222A5 (de)	1985-01-15	9-desoxy-9a-methylen-isostere von pgi-2 und verfahren zu deren herstellung.
EP0011591A1 (de)	1980-05-28	Neue Prostanderivate, ihre Herstellung und sie enthaltende Arzneimittel
CH636354A5 (de)	1983-05-31	Neue prostaglandin-i(2)-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
EP0119949B1 (de)	1988-11-23	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0099538B1 (de)	1991-09-11	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2627671A1 (de)	1977-01-13	Arzneimittel, enthaltend ein lacton eines prostaglandins oder prostaglandinanalogen
DE3121155A1 (de)	1982-12-09	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0057660B1 (de)	1985-08-21	Neue Prostacyclin-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
EP0105288B1 (de)	1985-12-11	Carbacycline, herstellung und verwendung
DE2517773A1 (de)	1976-10-28	Neue 11-oxo-prostaglandin-derivate und verfahren zu ihrer herstellung
EP0080061B1 (de)	1985-02-06	Neue cis-Bicyclo(3.3.0)octanderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen und Arzneimittel
EP0086404B1 (de)	1986-12-30	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0098794B1 (de)	1988-04-27	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0113311B1 (de)	1992-01-02	5-Fluorcarbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3006708A1 (de)	1980-09-25	Thromboxananaloge und thromboxanzwischenprodukte
EP0224275A1 (de)	1987-06-03	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0324815A1 (de)	1989-07-26	Neue 9-substituierte carbacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD234414A5 (de)	1986-04-02	Verfahren zur herstellung neuer carbacycline
DE3306125A1 (de)	1984-08-23	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3308561A1 (de)	1984-09-13	19,20-methylenprostacyclinderivate und verfahren zu ihrer herstellung
EP0434832A1 (de)	1991-07-03	D8- und D9-PROSTAGLANDIN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE PHARMAZEUTISCHE VERWENDUNG.
DD202010A5 (de)	1983-08-24	Verfahren zur herstellung neuer carbacycline
DD202287A5 (de)	1983-09-07	Verfahren zur herstellung von (13e)-(8r,11r,12r)-11,15-dihydroxy-16,19-dimethyl-9 oxo-13,18-prostadiensaeuren sowie deren salze